Literature DB >> 11310602

Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia.

O Josse1, D Labar, B Georges, V Grégoire, J Marchand-Brynaert.   

Abstract

[18F]-2-(2-Nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide ([18F]-EF3) has been prepared, in 65% chemical yield and 5% radiochemical yield, by coupling 2,3,5,6-tetrafluorophenyl 2-(2-nitroimidazol-1-yl) acetate 1 with [18F]-3,3,3-trifluoropropylamine 7. This original radiolabelled key-synthon was obtained in 40% overall chemical yield by oxidative [18F]-fluorodesulfurization of ethyl N-phthalimido-3-aminopropane dithioate 4, followed by deprotection with hydrazine of the resulting [18F]-N-phthalimido-3,3,3-trifluoropropylamine 5. All the process was performed within 90 min, from the [18F]-HF production in the cyclotron to the purification of the final target.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310602     DOI: 10.1016/s0968-0896(00)00279-0

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

Review 1.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 2.  Optimizing hypoxia detection and treatment strategies.

Authors:  Cameron J Koch; Sydney M Evans
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

3.  Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.

Authors:  Nicolas Christian; Anne Bol; Marc De Bast; Daniel Labar; John Lee; Pierre Mahy; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-03       Impact factor: 9.236

4.  Radiosynthesis of the tumor hypoxia marker [18F]TFMISO via O-[18F]trifluoroethylation reveals a striking difference between trifluoroethyl tosylate and iodide in regiochemical reactivity toward oxygen nucleophiles.

Authors:  Makiko Suehiro; Guangbin Yang; Geralda Torchon; Ellen Ackerstaff; John Humm; Jason Koutcher; Ouathek Ouerfelli
Journal:  Bioorg Med Chem       Date:  2011-02-18       Impact factor: 3.641

Review 5.  Multimodality imaging of hypoxia in preclinical settings.

Authors:  R P Mason; D Zhao; J Pacheco-Torres; W Cui; V D Kodibagkar; P K Gulaka; G Hao; P Thorpe; E W Hahn; P Peschke
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 2.346

6.  Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.

Authors:  P Mahy; M De Bast; P H Leveque; J Gillart; D Labar; J Marchand; V Gregoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

7.  [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.

Authors:  Ludwig Dubois; Willy Landuyt; Lieselotte Cloetens; Anne Bol; Guy Bormans; Karin Haustermans; Daniel Labar; Johan Nuyts; Vincent Grégoire; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

8.  Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.

Authors:  P Mahy; X Geets; M Lonneux; P Levêque; N Christian; M De Bast; J Gillart; D Labar; J Lee; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-04       Impact factor: 9.236

9.  Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.

Authors:  P Mahy; M De Bast; J Gillart; D Labar; V Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-08       Impact factor: 9.236

Review 10.  Radiosynthesis of [18)F]trifluoroalkyl groups: scope and limitations.

Authors:  V T Lien; P J Riss
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.